Clinical Trials ArenaOriginal article
Keenova seeks Xiaflex expansion on late-stage rare disease win
Phase 3XiaflexPositive
AI Analysis
Summary
Keenova's Xiaflex achieved late-stage trial success for plantar fibromatosis and is seeking FDA approval; if approved, it would be the first FDA-approved therapy for this rare disease.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Met
Outcome Details
late-stage rare disease trial success
Importance:6/10
Sentiment:
0.70
rare diseaseplantar fibromatosislate-stage trialFDA approval potentialfirst-in-class
Read the original article
Published by Clinical Trials Arena on July 9, 2026 10:21 AM